satralizumab 🐶 Veterinary Use | Indications/Contra | FAERs-F | FAERs-M | Orange Bk | BioActivity |

Stem definition	Drug id	CAS RN
humanized origin	5409	1535963-91-7

Description:

Molecule	Description
Molfile Synonyms: satralizumab satralizumab-mwge enspryng SA237 SA-237 RG-6168	Satralizumab-mwge is a recombinant humanized anti-human interleukin 6 (IL-6) receptor monoclonal antibody based on a human IgG2 framework. It is an interleukin-6 (IL-6) receptor antagonist indicated for the treatment of neuromyelitis optica spectrum disorder (NMOSD) in adult patients. The precise mechanism by which satralizumab-mwge exerts therapeutic effects in NMOSD is unknown but is presumed to involve inhibition of IL-6-mediated signaling through binding to soluble and membrane-bound IL-6 receptors. Molecular weight: Formula: CLOGP: LIPINSKI: None HAC: None HDO: None TPSA: ALOGS: ROTB: None

Molecule

Description

Molfile

Synonyms:

satralizumab
satralizumab-mwge
enspryng
SA237
SA-237
RG-6168

Satralizumab-mwge is a recombinant humanized anti-human interleukin 6 (IL-6) receptor monoclonal antibody based on a human IgG2 framework. It is an interleukin-6 (IL-6) receptor antagonist indicated for the treatment of neuromyelitis optica spectrum disorder (NMOSD) in adult patients. The precise mechanism by which satralizumab-mwge exerts therapeutic effects in NMOSD is unknown but is presumed to involve inhibition of IL-6-mediated signaling through binding to soluble and membrane-bound IL-6 receptors.

Molecular weight:
Formula:
CLOGP:
LIPINSKI: None
HAC: None
HDO: None
TPSA:
ALOGS:
ROTB: None

Drug dosage:

None

ADMET properties:

None

Approvals:

Date	Agency	Company
June 24, 2021	EMA	Roche Registration GmbH
Aug. 14, 2020	FDA	GENENTECH
June 29, 2020	PMDA	Chugai Pharmaceutical Co., Ltd.

FDA Adverse Event Reporting System (Female)

MedDRA adverse event term	Likelihood ratio	Likelihood ratio threshold	Patients taking drug having adverse event	Patients taking drug not having adverse event	Patients not taking drug having adverse event	Patients not taking drug not having adverse event
Urinary tract infection	47.75	39.40	25	333	264659	63224005
Myelitis	40.57	39.40	7	351	1396	63487268

FDA Adverse Event Reporting System (Male)

None

FDA Adverse Event Reporting System (Geriatric)

None

FDA Adverse Event Reporting System (Pediatric)

None

Pharmacologic Action:

Source	Code	Description
ATC	L04AC19	ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS IMMUNOSUPPRESSANTS IMMUNOSUPPRESSANTS Interleukin inhibitors

Drug Use | Suggest Off label Use Form| |View source of the data|

Disease	Relation	SNOMED_ID	DOID
Neuromyelitis optica	indication	25044007	DOID:8869
Tuberculosis	contraindication	56717001
Viral hepatitis type B	contraindication	66071002	DOID:2043

🐶 Veterinary Drug Use

None

🐶 Veterinary products

None

Acid dissociation constants calculated using MoKa v3.0.0

None

Orange Book patent data (new drug applications)

None

Orange Book exclusivity data (new drug applications)

None

Bioactivity Summary:

Target	Class	Pharos	UniProt	Action	Type	Activity value (-log[M])	Mechanism action	Bioact source	MoA source
Interleukin-6 receptor	Membrane receptor	P08887 P40189	IL6RA_HUMAN IL6RB_HUMAN	ANTAGONIST	Kd	8.82		DRUG LABEL	DRUG LABEL

External reference:

ID	Source
D11079	KEGG_DRUG
YB18NF020M	UNII
C4726732	UMLSCUI
CHEMBL3833307	ChEMBL_ID
DB15762	DRUGBANK_ID
9093	IUPHAR_LIGAND_ID
018474	NDDF
897234001	SNOMEDCT_US
897291006	SNOMEDCT_US
4039644	VANDF
4039645	VANDF
2391541	RXNORM
337831	MMSL
38756	MMSL
d09618	MMSL
C000655944	MESH_SUPPLEMENTAL_RECORD_UI
10065	INN_ID

Pharmaceutical products:

Product	Category	Ingredients	NDC	Form	Quantity	Route	Marketing	Label
Enspryng	HUMAN PRESCRIPTION DRUG LABEL	1	50242-007	INJECTION, SOLUTION	120 mg	SUBCUTANEOUS	BLA	28 sections
Enspryng	HUMAN PRESCRIPTION DRUG LABEL	1	50242-007	INJECTION, SOLUTION	120 mg	SUBCUTANEOUS	BLA	28 sections
Enspryng	HUMAN PRESCRIPTION DRUG LABEL	1	50242-007	INJECTION, SOLUTION	120 mg	SUBCUTANEOUS	BLA	28 sections